IL23A and spondyloarthropathy: The lack of efficacy of IL-23 blockade in axial (axial spondyloarthritis) but not peripheral (PsA) spondyloarthritis may be due to differences in IL-23 responsive cell types involved in disease pathogenesis and the timing of therapeutic intervention in the course of these diseases (95).